Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
Dazodalibep: A Comprehensive Analysis of a Novel CD40 Ligand Antagonist for Autoimmune Disease
Executive Summary
Dazodalibep is an investigational, second-generation therapeutic agent representing a significant potential advancement in the treatment of autoimmune diseases, most notably Sjögren's Syndrome. Classified as a non-antibody fusion protein, Dazodalibep functions as a highly specific antagonist of the CD40 ligand (CD40L), a critical component of the immune system's co-stimulatory axis. Its molecular architecture was strategically engineered to circumvent the severe thromboembolic toxicities that halted the development of first-generation anti-CD40L monoclonal antibodies, a feat achieved by eliminating the problematic Fc region. The drug's mechanism of action is centered on the blockade of the CD40/CD40L interaction, thereby disrupting the pathological communication between T cells, B cells, and other antigen-presenting cells that drives autoimmunity.
The clinical development program, now under the stewardship of Amgen following its acquisition of Horizon Therapeutics, is anchored by compelling results from a robust Phase 2, randomized, placebo-controlled, crossover trial (NCT04129164) in Sjögren's Syndrome. This study uniquely targeted two distinct patient populations: one with moderate-to-severe systemic disease activity and another with a high burden of patient-reported symptoms. Dazodalibep met its primary endpoints with high statistical significance in both groups, demonstrating a profound ability to reduce objective measures of systemic disease activity (measured by the ESSDAI score) and to provide clinically meaningful improvements in the debilitating symptoms of dryness, fatigue, and pain (measured by the ESSPRI score). The drug was found to be generally safe and well-tolerated, with no evidence of the thromboembolic events that plagued its predecessors.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/12/24 | Phase 3 | Recruiting | |||
2024/02/07 | Phase 3 | Recruiting | |||
2023/10/27 | Phase 3 | Active, not recruiting | |||
2022/01/21 | Phase 2 | Recruiting | |||
2019/11/22 | Phase 2 | Withdrawn | |||
2019/11/15 | Phase 2 | Completed | |||
2019/10/16 | Phase 2 | Completed | |||
2019/08/06 | Phase 2 | Completed | |||
2016/05/23 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.